Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Down 18.1% in April

Pyxis Oncology, Inc. (NASDAQ:PYXS) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 2,210,000 shares, a decline of 18.1% from the March 31st total of 2,700,000 shares. Based on an average daily trading volume, of 909,000 shares, the short-interest ratio is currently 2.4 days. Currently, 4.8% of the shares of the stock are sold short.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors have recently added to or reduced their stakes in the business. Cable Car Capital LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at $111,000. Vestal Point Capital LP acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at about $792,000. Decheng Capital LLC purchased a new position in Pyxis Oncology during the 4th quarter worth approximately $588,000. abrdn plc acquired a new position in Pyxis Oncology during the fourth quarter worth approximately $1,275,000. Finally, Decheng Capital Management III Cayman LLC purchased a new stake in Pyxis Oncology in the third quarter valued at approximately $650,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. BTIG Research started coverage on Pyxis Oncology in a report on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. SVB Leerink assumed coverage on Pyxis Oncology in a research report on Tuesday, January 23rd. They issued an “outperform” rating and a $12.00 price objective for the company. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research report on Tuesday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Friday, March 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Wednesday, April 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $8.50.

Pyxis Oncology Stock Performance

Shares of PYXS stock remained flat at $4.30 during trading on Friday. 164,540 shares of the company were exchanged, compared to its average volume of 649,712. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85. The company has a fifty day simple moving average of $5.10 and a 200-day simple moving average of $3.25.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, March 21st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. On average, research analysts forecast that Pyxis Oncology will post -0.85 EPS for the current fiscal year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.